Global Human Papillomavirus (HPV) Therapeutics Market 2023-2027

Description

List of Tables

Technavio has been monitoring the human papillomavirus (HPV) therapeutics market and is forecast to grow by $953.3 mn during 2022-2027, accelerating at a CAGR of 5.15% during the forecast period. Our report on the human papillomavirus (HPV) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by advent of vaccines, development of oral vaccines for HPV, and strong disease progression.

Technavio's human papillomavirus (HPV) therapeutics market is segmented as below:

By Route of Administration

Parenteral
Topical

By Indication

Cervical cancer
Anal cancer
Vulvar and vaginal cancer
Others

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the r and d of new drugs for orthostatic hypotension treatment as one of the prime reasons driving the human papillomavirus (HPV) therapeutics market growth during the next few years. Also, use of combination therapy in treatment and the adoption of fludrocortisone as off label first line pharmacotherapy will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the human papillomavirus (HPV) therapeutics market covers the following areas:

Human papillomavirus (HPV) therapeutics market sizing
Human papillomavirus (HPV) therapeutics market forecast
Human papillomavirus (HPV) therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human papillomavirus (HPV) therapeutics market vendors that include 2A Pharma ApS, AbbVie Inc., Bavarian Nordic AS, BioVaxys Technology Corp., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ISA Pharmaceuticals BV, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Xiamen Innovax Biotech Co. Ltd., Merck and Co. Inc., Bausch Health Co. Inc., and Inovio Pharmaceuticals Inc. Also, the human papillomavirus (HPV) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR72565

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 06: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global Human Papillomavirus (HPV) therapeutics market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global Human Papillomavirus (HPV) therapeutics market 2017 - 2021 ($ million)
4.2 route of administration Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - route of administration Segment 2017 - 2021 ($ million)
4.3 Indication Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Indication Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Route of Administration

6.1 Market segments
Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
6.2 Comparison by Route of Administration
Exhibit 32: Chart on Comparison by Route of Administration
Exhibit 33: Data Table on Comparison by Route of Administration
6.3 Parenteral - Market size and forecast 2022-2027
Exhibit 34: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
6.4 Topical - Market size and forecast 2022-2027
Exhibit 38: Chart on Topical - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Topical - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Topical - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Topical - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Route of Administration
Exhibit 42: Market opportunity by Route of Administration ($ million)
Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)

7 Market Segmentation by Indication

7.1 Market segments
Exhibit 44: Chart on Indication - Market share 2022-2027 (%)
Exhibit 45: Data Table on Indication - Market share 2022-2027 (%)
7.2 Comparison by Indication
Exhibit 46: Chart on Comparison by Indication
Exhibit 47: Data Table on Comparison by Indication
7.3 Cervical cancer - Market size and forecast 2022-2027
Exhibit 48: Chart on Cervical cancer - Market size and forecast 2022-2027 ($ million)
Exhibit 49: Data Table on Cervical cancer - Market size and forecast 2022-2027 ($ million)
Exhibit 50: Chart on Cervical cancer - Year-over-year growth 2022-2027 (%)
Exhibit 51: Data Table on Cervical cancer - Year-over-year growth 2022-2027 (%)
7.4 Anal cancer - Market size and forecast 2022-2027
Exhibit 52: Chart on Anal cancer - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Data Table on Anal cancer - Market size and forecast 2022-2027 ($ million)
Exhibit 54: Chart on Anal cancer - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on Anal cancer - Year-over-year growth 2022-2027 (%)
7.5 Vulvar and vaginal cancer - Market size and forecast 2022-2027
Exhibit 56: Chart on Vulvar and vaginal cancer - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Data Table on Vulvar and vaginal cancer - Market size and forecast 2022-2027 ($ million)
Exhibit 58: Chart on Vulvar and vaginal cancer - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Vulvar and vaginal cancer - Year-over-year growth 2022-2027 (%)
7.6 Others - Market size and forecast 2022-2027
Exhibit 60: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Indication
Exhibit 64: Market opportunity by Indication ($ million)
Exhibit 65: Data Table on Market opportunity by Indication ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share by geography 2022-2027 (%)
Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 91: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 Canada - Market size and forecast 2022-2027
Exhibit 95: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.10 China - Market size and forecast 2022-2027
Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
9.11 Brazil - Market size and forecast 2022-2027
Exhibit 103: Chart on Brazil - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on Brazil - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on Brazil - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on Brazil - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity by geography
Exhibit 107: Market opportunity by geography ($ million)
Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 2A Pharma ApS
Exhibit 115: 2A Pharma ApS - Overview
Exhibit 116: 2A Pharma ApS - Product / Service
Exhibit 117: 2A Pharma ApS - Key offerings
12.4 AbbVie Inc.
Exhibit 118: AbbVie Inc. - Overview
Exhibit 119: AbbVie Inc. - Product / Service
Exhibit 120: AbbVie Inc. - Key news
Exhibit 121: AbbVie Inc. - Key offerings
12.5 Bausch Health Co. Inc.
Exhibit 122: Bausch Health Co. Inc. - Overview
Exhibit 123: Bausch Health Co. Inc. - Business segments
Exhibit 124: Bausch Health Co. Inc. - Key news
Exhibit 125: Bausch Health Co. Inc. - Key offerings
Exhibit 126: Bausch Health Co. Inc. - Segment focus
12.6 Bavarian Nordic AS
Exhibit 127: Bavarian Nordic AS - Overview
Exhibit 128: Bavarian Nordic AS - Product / Service
Exhibit 129: Bavarian Nordic AS - Key offerings
12.7 BioVaxys Technology Corp.
Exhibit 130: BioVaxys Technology Corp. - Overview
Exhibit 131: BioVaxys Technology Corp. - Product / Service
Exhibit 132: BioVaxys Technology Corp. - Key offerings
12.8 F. Hoffmann La Roche Ltd.
Exhibit 133: F. Hoffmann La Roche Ltd. - Overview
Exhibit 134: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 135: F. Hoffmann La Roche Ltd. - Key news
Exhibit 136: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 137: F. Hoffmann La Roche Ltd. - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 138: GlaxoSmithKline Plc - Overview
Exhibit 139: GlaxoSmithKline Plc - Business segments
Exhibit 140: GlaxoSmithKline Plc - Key offerings
Exhibit 141: GlaxoSmithKline Plc - Segment focus
12.10 Inovio Pharmaceuticals Inc.
Exhibit 142: Inovio Pharmaceuticals Inc. - Overview
Exhibit 143: Inovio Pharmaceuticals Inc. - Product / Service
Exhibit 144: Inovio Pharmaceuticals Inc. - Key news
Exhibit 145: Inovio Pharmaceuticals Inc. - Key offerings
12.11 ISA Pharmaceuticals BV
Exhibit 146: ISA Pharmaceuticals BV - Overview
Exhibit 147: ISA Pharmaceuticals BV - Product / Service
Exhibit 148: ISA Pharmaceuticals BV - Key offerings
12.12 Merck and Co. Inc.
Exhibit 149: Merck and Co. Inc. - Overview
Exhibit 150: Merck and Co. Inc. - Business segments
Exhibit 151: Merck and Co. Inc. - Key news
Exhibit 152: Merck and Co. Inc. - Key offerings
Exhibit 153: Merck and Co. Inc. - Segment focus
12.13 Serum Institute of India Pvt. Ltd.
Exhibit 154: Serum Institute of India Pvt. Ltd. - Overview
Exhibit 155: Serum Institute of India Pvt. Ltd. - Product / Service
Exhibit 156: Serum Institute of India Pvt. Ltd. - Key offerings
12.14 Walvax Biotechnology Co. Ltd.
Exhibit 157: Walvax Biotechnology Co. Ltd. - Overview
Exhibit 158: Walvax Biotechnology Co. Ltd. - Product / Service
Exhibit 159: Walvax Biotechnology Co. Ltd. - Key offerings
12.15 Xiamen Innovax Biotech Co. Ltd.
Exhibit 160: Xiamen Innovax Biotech Co. Ltd. - Overview
Exhibit 161: Xiamen Innovax Biotech Co. Ltd. - Product / Service
Exhibit 162: Xiamen Innovax Biotech Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 163: Inclusions checklist
Exhibit 164: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 165: Currency conversion rates for US$
13.4 Research methodology
Exhibit 166: Research methodology
Exhibit 167: Validation techniques employed for market sizing
Exhibit 168: Information sources
13.5 List of abbreviations
Exhibit 169: List of abbreviations